NEW YORK, NY / ACCESS Newswire / March 18, 2026 / Global energy markets operate in a constant state of flux, where pricing pressures, geopolitical tensions, and shifting logistics can alter supply dynamics in an instant. In this environment, absolute trust has become a premium asset. SMX (Security Matters) PLC (NASDAQ:SMX; SMXWW) introduces a new layer of authenticity through its advanced traceability platform, enabling crude oil, refined fuels, and petrochemical products to carry a persistent, verifiable identity throughout their journey-helping defend the enormous capital investments that underpin the global energy system while equipping stakeholders with real-time intelligence.
The impact of SMX’s technology extends across every node of the energy value chain. Producers are able to preserve the integrity and market value of their output. Transporters and traders gain confirmation that materials remain consistent and untampered with in transit. Refiners and distributors can validate the authenticity of feedstocks entering their systems. Regulators and government bodies are better positioned to enforce sanctions, ensure compliance, and monitor cross-border flows. Meanwhile, investors and financial markets benefit from enhanced transparency surrounding the origin and movement of energy assets that drive global trade.
Each year, petroleum commodities valued in the trillions move through an intricate web of pipelines, vessels, storage facilities, refineries, and trading centers spanning multiple countries and regulatory regimes. Within these complex pathways, materials can be altered-whether through blending, substitution, dilution, relabeling, or diversion-introducing significant financial exposure, compliance risks, and reputational challenges.
SMX addresses these vulnerabilities by embedding microscopic, undetectable markers directly into the commodities themselves. These markers create a lasting, traceable signature that travels with the material across every stage of its lifecycle-from production and transport to storage, processing, and end delivery.
This approach represents a departure from conventional tracking systems that rely on external documentation. Instead, SMX anchors verification within the physical product, transforming each barrel or batch into its own source of truth.
By linking this embedded signature to a secure digital verification framework, SMX enables the creation of a continuous, auditable record of origin and movement. The result is a unified physical-digital identity system that enhances visibility across global energy supply chains while reinforcing the value and security of the assets involved.
Given the scale of capital deployed across energy infrastructure-from upstream extraction to downstream distribution-ensuring the authenticity of materials moving through these systems is no longer optional. It is central to protecting both operational integrity and financial performance.
SMX’s markers are engineered to integrate seamlessly into existing industrial workflows without affecting the chemical composition or performance of the materials. They can be introduced during production or refining and later authenticated through proprietary detection technologies.
In a world where energy markets react in real time and disruptions can ripple across continents overnight, SMX delivers a critical advantage: embedded verification at the source-providing clarity, accountability, and actionable insight for those responsible for powering, regulating, and investing in the global energy economy.
BOULDER, CO / ACCESS Newswire / March 18, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal health care, today announced the launch of Aquanil® AD, a hypochlorous acid based dermatology product line for sensitive skin, developed exclusively for Persōn & Covey, Inc. for distribution through its established over-the-counter dermatology channels in the United States.
The Aquanil AD product line includes Aquanil AD Repair Mist, a soothing spray for irritated or damaged skin; Aquanil AD Recovery Gel, designed to help reduce the appearance of scars; and Aquanil AD Rescue Serum for relief from rashes, itching and irritation. Each product was specifically designed for sensitive or reactive skin.
“The incomparable safety profile of Sonoma’s Microcyn technology made it an ideal choice for our Aquanil line and our commitment to providing relief for individuals with sensitive skin,” remarked Marisa Brenninkmeyer, CEO of Persōn & Covey. “We are thrilled to make hypochlorous acid-based products available to our customers, as we know the dermatological benefits of HOCl.”
“We are excited to partner with such a highly regarded company as Persōn & Covey, whose dedication to those with sensitive skin aligns with Sonoma’s mission to provide safe and effective skin care solutions,” noted Amy Trombly, CEO of Sonoma. “We look forward to growing this partnership and sharing our technology with more consumers across the United States.”
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma’s products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma’s products are sold either directly or via partners in over 55 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
About Persōn & Covey
Persōn & Covey, Inc. has been a pioneer in the field of health and personal care since its founding by chemist Lorne V. Persōn in 1941. The family-owned California-based company has grown with each generation to offer an ever-widening line of internationally distributed products. From its beginning, Persōn & Covey has worked closely with the medical community to develop high-quality therapeutic formulas, especially in the areas of sun protection and dermatological care. Today the company continues to create revolutionary products for use by medical professionals and their patients. Recognizing that each patient is unique, Persōn & Covey carefully crafts products that are appropriate for use by even the most sensitive of users. Through its commitment to combining cutting-edge science with cosmetic elegance, Persōn & Covey is proud to continue its tradition of providing outstanding health and beauty solutions. More information can be found at www.personandcovey.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “develop,” “anticipate,” “expect” and “opportunities,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
MVID has a lethal natural history requiring life-sustaining parenteral support (PS), which includes total parenteral nutrition (TPN), which is associated with significant toxicities; PS reduction could potentially reduce co-morbidities and improve clinical benefit, as no approved therapies exist for MVID
Jaguar launches news alert text service for investors – click here to sign up for text alerts
SAN FRANCISCO, CA / ACCESS Newswire / March 18, 2026 / Jaguar Health, Inc.(NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that, based on the U.S. Food and Drug Administration (FDA) support for Napo’s protocol amendment for its clinical trial to evaluate the safety and efficacy of its novel crofelemer powder-for-oral-solution formulation in pediatric patients with intestinal failure due to MVID, an ultrarare pediatric disorder, Napo plans to initiate a single-blind extension phase for the trial. The extended treatment period has the potential to improve clinical benefit of crofelemer through reduction of parenteral support (PS) requirements, which may result in disease progression-modification of MVID.
“We are pleased to have the opportunity to continue treatment with crofelemer powder for oral solution in our ongoing clinical trial of crofelemer in pediatric MVID patients,” said Pravin Chaturvedi, PhD, Jaguar’s Chief Scientific Officer and Chair of the Jaguar and Napo Scientific Advisory Board. “This would allow patients who have completed their double-blind treatment period to be eligible for the single-blind phase of continued treatment with crofelemer for further assessment of clinical benefit through reduction of PS for a longer period. PS reduction could potentially reduce co-morbidities associated with the disease and TPN; thus improving clinical benefit and modifying the disease progression to help address the lethal natural history of MVID.”
The dose selection for the single-blind extension phase will be determined by the study’s independent Data Monitoring Committee (DMC), which will ensure that the study clinicians and Napo personnel will remain blinded. Currently, approximately 30% of the participating MVID patients have completed the study’s double-blind treatment phase and the clinical investigators are supporting the patients’ participation in the single-blind extended phase.
This trial of crofelemer in MVID patients has clinical sites in the US, Italy and the UAE, and the consent from the FDA, the European Medicines Agency (EMA), The Ministry of Health and Prevention (MOHAP), and the Institutional Review Boards (IRBs) for each site.
“Our development plan for this ultrarare disease, with an expected improved clinical benefit from the longer treatment in the extension phase, may also support the possibility for a Breakthrough Therapy designation from the FDA in the coming months, potentially supporting opportunities for expedited regulatory submission pathways to the FDA for new drug approval for this ultrarare pediatric disorder,” said Lisa Conte, Jaguar’s founder, president, and CEO. “The extremely low incidence and prevalence of MVID, its lethal natural history and the fact that no therapies are available for MVID other than lifelong PS, underscores the need for new therapies. Together with the support of MVID clinical key opinion leaders (KOLs), we are exploring expedited regulatory pathways for crofelemer.”
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that Napo will initiate a single-blind extension phase for its MVID trial, the expectation that PS reduction could potentially reduce co-morbidities associated with MVID and TPN, thus improving clinical benefit and modifying the disease progression to help address the lethal natural history of MVID, and Jaguar’s expectation that its development plan for MVID may support the possibility for a Breakthrough Therapy designation from the FDA in the coming months, potentially supporting opportunities for expedited regulatory submission pathways to the FDA for new drug approval. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CE From Amber Book is Structured for How Engineers Want to Grow and Accelerate Their Careers
BLACKSBURG, VA / ACCESS Newswire / March 18, 2026 / Built for engineers and designed by engineers who understand the realities of modern practice, Amber Book Continuing Education for Engineers was created to move CE beyond checkbox compliance and toward meaningful professional growth.
Rather than relying on passive slides and outdated examples, Amber Book develops courses around real engineering challenges – helping engineers apply lessons immediately on the job: strengthening technical judgement, staying current with evolving tools, and building adjacent skills relative to varied project work. This approach reflects what has been shifting in the profession: Engineers increasingly expect CE to support career advancement, not just licensure renewal.
“Engineering school teaches you the fundamentals of how to think critically, model systems, and solve complex problems. The practical tools we use evolve all the time, but that’s nothing new. What’s different now is how fast we can learn and apply new methods, connecting those same fundamentals to the challenges we face in real projects,” said Yaw Bangolame, P.E., National Engineering Expert at Amber Book. “We create actionable learning that’s timely, practical, and created to help engineers connect theory with the real tools and workflows used in today’s projects, as an ongoing next step to foundational education.”
The three newest courses added to the Amber Book Continuing Education for Engineers catalogue reflect this commitment to purposeful, career-relevant learning. Each course was selected to address modern engineering workflows, emerging technologies, and real-world decision-making engineers face today – often underserved by traditional CE providers. Together, they exemplify Amber Book’s belief that continuing education should sharpen skills, expand perspective, and prepare engineers to lead in an evolving industry.
With increasingly complex stormwater management opportunities, made imperative by environmental density, extreme climate shifts, and the regulatory pressure for flood mitigation as an outcome, “Modeling Urban Stormwater Pipe Networks in HEC-RAS 6.7″ is a timely course for engineers to design and build systems that can withstand urban growth and climate realities. From aspects like computational methodologies and parameters to conversion tools, learners benefit from a structured walkthrough of the HEC-RAS 6.7 stormwater module – covering integrated 2D-pipe simulation, and applied concepts to realistic scenarios. Access course objectives here.
Engineers need to know how to actually do the work in industry software, not just the theoretic concepts needed for flood studies and infrastructure modeling. The technical execution skills delivered in “Analyzing and Visualizing Results in HEC-RAS” help engineers navigate the RAS Mapper to capture results including depth, velocity, and water-surface elevation; how to apply settings, produce defensible mapping, and interpret key diagnostic variables, to name a few. Delivering confidence and defensibility to stakeholders and regulators, learn more about the course objectives here.
Transportation engineers are a critical component in combatting the rise of fatalities in pedestrians and cyclists, and with the popularity of scooters and more advanced mobility support, engineers are positioned to identify risk patterns and prioritize safety strategies. The “Generative AI (GenAI) and Transportation: Applications in Vulnerable Road User (VRU) Safety Platform” helps engineers develop data-driven safety interventions for all vulnerable road users and act with AI analysis versus static crash reports. Covering foundational concepts, along with practical applications – including how to integrate spatial tools like ArcGIS to identify high-risk crash locations – engineers can pinpoint safety interventions and gain more AI literacy for the next generation of planning. Learn more about course objectives and purchase here.
With continuing education deadlines approaching across multiple states, Amber Book Continuing Education for Engineers provides a practical path for professionals who want CE that goes beyond mere compliance. Engineers can earn PDHs while engaging with timely, relevant content designed to strengthen real-world capability – not just check a box. Those with upcoming state deadlines, take heed: Texas has a deadline of 3/31/26, while those in Kansas and New Jersey have to comply by 4/30/26.
Whether completing a single course or exploring the full catalogue, Amber Book gives engineers the flexibility to learn at their own pace, go deeper across disciplines, and stay ahead of what modern engineering practice demands.
About Amber Book
Amber Book is a professional education company specializing in innovative learning experiences for architects, design professionals, and now engineers. Often these two industries, architecture and engineering, work together for the built world. Committed to advancing licensure success and professional growth, Amber Book offers flexible, self-paced learning with visually engaging, interactive content with real-world applications. As a leader in Architect Registration Exam® preparation and continuing education, Amber Book empowers architects at every stage of their careers – from licensure preparation to lifelong learning. With over 42,000 learners enrolled, over 1,700 firms partnered, and an average ARE® 5.0 pass rate of 81 percent, Amber Book is a trusted resource for architects, architecture, and engineering firms. For more information, visit AmberBook.com. Amber Book is part of the Career Certified family of educators. Learn more at CareerCertified.com.
The 2026 Pros to Know Awards recognizes outstanding executives who serve as an example for other leaders looking to leverage supply chain for competitive advantage.
COLUMBUS, OH / ACCESS Newswire / March 18, 2026 / Josh Medow, CEO of Mercury, a healthcare and life sciences logistics company specializing in international cold-chain shipping, has been named a Rising Star in the 2026 Pros to Know Awards by Supply & Demand Chain Executive, the only publication covering the entire global supply chain.
“When it comes to overcoming supply chain disruption, this year’s pack of supply chain leaders left no stone unturned,” says Marina Mayer, editor-in-chief of Food Logistics and Supply & Demand Chain Executive and co-founder of the Women in Supply Chain Forum. “From AI implementation and warehouse automation to last-mile accuracy and returns management, they innovated, developed and executed on all cylinders, providing solutions, technologies and processes that move product from Point A to Point B in a way that almost seems seamless. And every year, I am honored to celebrate these supply chain professionals.”
Medow became CEO of Mercury in 2020 with the goal of making life sciences and healthcare shipping simple. During his tenure, Mercury has grown by over 123% and has a 99.6% success rate in international cold-chain shipping, supporting biotech, pharmaceutical, and research industries worldwide. He remains hands-on and customer-focused, personally reviewing every new lead and client journey within their portal. His goal is to create systems and shifts that provide accurate and timely deliveries for each customer.
“Being named a Rising Star in the logistics industry is an honor,” said Medow. “But, it is more of a reflection on the company and team as a whole. Mercury’s dedication to our customers, commitment to proactively seek out solutions, and focus on improvement is unmatched. Our clients cannot afford delays or reroutes when shipping life-saving products. I’m proud to say our entire team understands the urgency and important role logistics plays in research, treatments, and patient care.”
Supply & Demand Chain Executive is the only supply chain publication covering the entire global supply chain, focusing on trucking, warehousing, packaging, procurement, risk management, professional development and more. Supply & Demand Chain Executive and its sister publication, Food Logistics, also operate SCN Summit and the Women in Supply Chain Forum. Go to www.SDCExec.com to learn more.
About IRONMARKETS
IRONMARKETS, formerly known as AC Business Media, is a leading business-to-business media and buyer engagement platform with a portfolio of renowned brands in heavy construction, asphalt, concrete, paving, rental, sustainability, landscape, manufacturing, logistics, and supply chain markets. IRONMARKETS delivers relevant, cutting-edge content through its industry-leading digital properties, trade shows, conferences, videos, magazines, webinars, and newsletters. Learn more at https://www.iron.markets.
PLANO, TX / ACCESS Newswire / March 18, 2026 / ZeOmega, the industry’s leading population health management organization, today announced it was listed in Gartner’s 2026 Market Guide for Intelligent Prior Authorization. The report names ZeOmega as a Representative Vendor in the intelligent prior authorization (iPA) market and mentions the company’s Smart Auth Optimizer solution’s capabilities designed to streamline prior authorization workflows using AI and automation.
Prior authorization remains one of the most labor-intensive and time-consuming processes in healthcare, often relying on manual faxes and phone calls. At the same time, new regulatory mandates such as CMS-0057 are pushing organizations to implement greater transparency and API-enabled workflows.
ZeOmega’s Smart Auth Optimizer applies AI and workflow automation to support real-time data exchange between payers and providers, helping organizations meet evolving requirements while reducing manual administrative burdens and streamlining the care approval process.
“As payers and providers face mounting financial and regulatory pressures, inefficiencies in prior authorization workflows amplify the strain,” said Suhas Ramachandra, VP, Product Strategy and Innovation, ZeOmega. “We believe ZeOmega’s recognition in this Gartner Market Guide reflects our continued commitment to helping healthcare organizations streamline prior authorization processes, improve efficiency and ultimately support faster access to care.”
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About ZeOmega ZeOmega empowers health plans and other risk-bearing organizations with the industry’s leading technology for simplifying population health management. Clients using ZeOmega’s Jiva Healthcare Enterprise Management Platform experience superior workflow and proven results due to exceptional integration capabilities, unmatched clinical content, and a powerful rules engine. With deep domain expertise and a comprehensive understanding of population health challenges, ZeOmega serves as a true partner for clients with personalized deployment and delivery models. By consistently exceeding customer expectations and project benchmarks, ZeOmega has earned a reputation for being proactive, reliable, and dedicated to improving the health of its clients’ members. ZeOmega was named Best in KLAS for Payer Care Management Solutions in 2022, 2023, 2024, and 2025. Founded in 2001, ZeOmega is privately held and headquartered in Plano, Texas.
ZeOmega and Jiva are registered trademarks or trademarks of ZeOmega, Inc. or its subsidiaries in the United States and other countries. Other marks or brands may be claimed as the property of others.
Modulate’s ELM model architecture unlocks transcription for the masses, cutting costs by 10x while achieving industry-leading accuracy.
BOSTON, MA / ACCESS Newswire / March 18, 2026 / Modulate, the frontier conversational voice intelligence company, today announced Velma Transcribe, a speech-to-text API delivering high-accuracy, low-latency transcription at 90% lower cost per hour than other leading transcription providers. This significantly lower price point represents a fundamental shift in the economics of transcription. For a fraction of the cost, Modulate unlocks affordable speech-to-text transcription for every audio conversation in the world, empowering real-time voice agents, call center platforms, social apps, and more with industry-leading transcription tools at a global scale.
Built using Modulate’s industry-leading Ensemble Listening Model (ELM) research, Velma Transcribe orchestrates an ensemble of specialized transcription models to improve accuracy, latency, and cost efficiency compared to any single model. In addition to the outstanding unit economics, Velma Transcribe achieves industry-leading results on widely used datasets, including Earnings-22 and the AMI Meeting Corpus. The result is a new standard for conversational audio transcription, combining strong accuracy on complex multi-speaker audio with dramatically improved unit economics for processing voice data at scale.
“Modulate is the world leader in using voice understanding AI, and our goal is to make the tools to understand audio available to anyone, at any scale,” said Carter Huffman, CTO and Cofounder of Modulate. “Our full ensemble for conversation understanding, Velma, already outperforms LLMs in recognizing key behaviors, and now Velma Transcribe makes one of our core underlying capabilities available directly to developers who simply need accurate transcripts, not behavioral insights.”
In addition, Velma Transcribe offers features built for Enterprise use cases:
Emotion detection (20+ emotions)
Accent detection (20+ accents)
Multilingual (70+ languages)
PII redaction, diarization, streaming support, and more
Lower Transcription Costs By up to 10X
Velma Transcribe reduces transcription costs to approximately $0.03 per hour of audio, more than 90% lower than leading providers. These economics make it far more cost-effective for enterprise organizations to analyze and monetize their voice data.
$0.03 – Modulate Velma Transcribe
$0.40 – ElevenLabs Scribe v2
$0.31 – Deepgram Nova-3
$0.26 – Deepgram Nova-2
$0.21 – AssemblyAI Universal-3 Pro
*Based on publicly listed pricing as of March 18, 2026
Compare the leading speech-to-text transcription companies on cost and accuracy at Speechtxt.com.
Top Marks for Conversational Audio Accuracy at Scale
Velma Transcribe is engineered for real-world conversations that challenge traditional systems, including overlapping speakers, interruptions, accents, and background noise. On the AMI Meeting Corpus dataset, a widely used benchmark for complex multi-speaker conversational audio, Velma avoids over 40% of the errors made by Eleven Labs and over 70% of the errors made by OpenAI GPT-4o-transcribe.
Huffman explains the top marks, “We’ve tuned Velma for conversational audio, including emotion and accent detection, leading to materially lower error rates on meeting and call data while delivering dramatic cost savings versus incumbent providers. That combination makes high-quality transcription practical at scale.”
Built for Secure Enterprise Voice Production
Velma Transcribe includes all the capabilities developers expect and enterprise operations need, including:
Batch and streaming transcription endpoints with structured output and segment timestamps
Zero data stored, ensuring privacy-safe workflows
Sub-second streaming latency with partial transcripts for live applications and agent pipelines
Robust formatting optimized for conversational speech and long recordings
Broad language coverage in 70 of the world’s most commonly spoken languages
Personally Identifiable Information (PII) detection and redaction
Advanced transcription enrichments, including speaker diarization, emotion detection, and accent identification
Backed by Modulate’s security practices and ISO 27001 certification, these capabilities allow developers to build secure, voice-enabled applications and help organizations extract insights from large volumes of conversational data.
Models that Listen and Understand
Velma Transcribe is part of Modulate’s growing family of Velma 2.0 voice analytics models built to deliver a new, context-rich listening layer for AI systems. It represents the first step in Modulate’s expanding developer API strategy, with additional capabilities planned across synthetic voice detection, emotion analysis, and deeper conversational intelligence. Together, these capabilities allow developers and enterprises to move beyond transcription to understand how conversations unfold, enabling applications such as fraud detection, customer sentiment analysis, compliance monitoring, and real-time decision support.
“The industry has spent years teaching AI how to generate and respond. The next frontier is teaching it how to listen,” said Mike Pappas, CEO and Cofounder of Modulate. “Most systems today rely on transcription, reducing rich conversations to flat text and losing the signals humans naturally understand. Velma is the listening layer for AI, giving developers and enterprises the ‘ears’ needed to build voice-native applications that can capture the nuance and intent within spoken dialogue.”
Availability and Pricing
Velma Transcribe is available today with batch and sub-second streaming transcription. Modulate pricing is usage-based and optimized for high-volume workloads: https://www.modulate.ai/pricing
About Modulate
Modulate is a voice intelligence company building AI models and APIs designed to understand real-world conversational audio at scale. Its technology combines speech recognition, acoustic analysis, and conversational context to deliver reliable, explainable, and cost-effective voice intelligence for developers and enterprises.
For more information or to get started, visit modulate.ai.
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.
PHILADELPHIA, PA / ACCESS Newswire / March 18, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, announced today that members of its executive management team, led by Dr. Raza Bokhari, Executive Chairman & CEO, will participate in a live fireside chat on Thursday, March 19, 2026, hosted by Kumaraguru (Kumar) Raja, Ph.D., Senior Biotechnology Analyst at Brookline Capital Markets.
Event:
Fireside Chat with Kumar Raja, Brookline Capital Markets
Dr. Bokhari will provide a company update including a review of the positive SkinJect® SKNJCT-003 Phase 2 clinical trial topline results that were reported earlier this month.
Key findings of the study include 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.
The SKNJCT-003 Phase 2 study is a “randomized, double-blind, three-arm Phase 2 study evaluating two dose levels of microneedle-mediated delivery of doxorubicin compared with a device-only control in patients with nodular basal cell carcinoma.
Previously reported Topline results of the clinical clearance of study are tabulated below:
Table 1. Clinical Clearance by Treatment Arm
Treatment Arm
# of patients (47)
Clinical clearance (Day 29)
# of patients (43)
Clinical Clearance (Day 57)
200 μg D-MNA
15
40%
15
73%
P-MNA
15
33%
16
38%
100 μg D-MNA
17
47%
12
42%
P-MNA: Microneedle device-only control arm D-MNA: Doxorubicin-loaded microneedle array
The study results demonstrate clear separation in clinical response between the D-MNA treatment arm (73%) and P-MNA treatment arm (38%) in the 200-µg cohort at Day 57, supporting the continued development of SkinJect as a potential non-surgical treatment option for patients with basal cell carcinoma.
The dataset reflects two complementary components of the SkinJect mechanism:
Biologic activity from the microneedle delivery platform
Additional tumor-killing activity from the chemotherapeutic agent
Biological Activity of the Microneedle Device-Only Control (P-MNA)
The SKNJCT-003 study included a microneedle device-only control arm (P-MNA) that did not contain the chemotherapeutic agent. Microneedle insertion into tumor tissue is known to produce localized biological activity, including:
mechanical disruption of tumor architecture
activation of wound-healing pathways
localized immune signaling
Basal cell carcinoma is recognized as a highly immunogenic tumor, and these localized biological responses are designed to contribute to tumor regression even without drug loading.
The Company previously observed similar biological effects in:
the SKNJCT-001 Phase 1 safety study (2021)
the interim analysis of SKNJCT-003 in March 2025
Separation Between Drug and Device Arms
The SKNJCT-003 study demonstrated substantially higher clinical clearance in the drug-loaded microneedle cohort compared with the device-only control arm atDay 57:
200-µg D-MNA cohort: 73% clinical clearance
P-MNA cohort: 38% clinical clearance
Importantly, the magnitude of response observed in the active treatment cohort relative to the device-only control arm provides clinically meaningful evidence of drug-mediated therapeutic effect within a biologically active microneedle delivery platform.
The Company believes the dataset represents decision-grade evidence supporting continued development of the SkinJect program and advancement toward regulatory discussions and potential strategic partnerships.
The fireside chat will conclude with a Q&A session during which participants can ask questions. Please note this event will be live only; there will be no publicly available recording or archived webcast.
Medicus Pharma Ltd. (Nasdaq:MDCX) is a precision-guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries across three continents.
Company’s key therapeutics assets are:
SkinJect™, a novel localized immuno-oncology precision product focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) and Gorlin Syndrome, a rare autosomal dominant disease also called nevoid BCC syndrome, collectively representing an ~$2 billion market opportunity.
Teverelix®, a next generation GnRH antagonist is a first-in-market product for cardiovascular high-risk advanced prostate cancer patients and patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate, collectively representing an ~$6 billion market opportunity.
The Company actively engaged in following collaborations:
Skinject™ Platform Expansion
In August 2025, the Company announced its entry into a non-binding memorandum of understanding (MoU) with Helix Nanotechnologies, Inc. (HelixNano), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed, and there can be no assurance that such definitive agreements will be executed.
The Company is exploring co-development of thermostable infectious disease vaccines combining HelixNano’s proprietary mRNA technology with the Medicus microneedle array delivery platform.
Patient Access and Advocacy
In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.
In collaboration with the Gorlin Syndrome Alliance, Medicus is pursuing an Expanded Access IND program to provide Gorlin Syndrome patients with multiple or inoperable BCCs access to SkinJect™, the Company’s investigational D-MNAs, under physician supervision.
AI Enabled Clinical Development
In December 2025, the Company signed a non-binding letter of intent to collaborate with Reliant AI Inc., a decision-intelligence company specializing in generative AI for the life sciences, to develop an AI-driven clinical data analytics platform to support capital-efficient and time-efficient clinical development through data-driven dynamic clinical-site selection, pharmacodynamic (PD) informed patient stratification, and enrollment forecasting. The initial phase of the collaboration is expected to support the upcoming Teverelix clinical study planned for 2026. There can be no assurance that a definitive agreement will be executed or that the proposed collaboration will proceed as contemplated.
Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company’s leadership and prospects, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect™), ability to be approved for the Expanded Access IND Program to enable those suffering with Gorlin Syndrome to access SkinJect™ under physician-supervised treatment protocols, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr, high CV risk prostate cancer, women’s health indications like endometriosis, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, including with respect to the Company’s submission for approval in the FDA Commissioner’s National Priority Voucher program, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the Company’s expectations regarding reported efficacy findings and whether there will be material changes to its reported SKNJCT-003 topline results and to secure an EOP2 meeting with the FDA in the first half of 2026, entry into definitive documents with Reliant and the expected terms thereof, engaging in proposed Medicus-sponsored studies currently contemplated in the Reliant non-binding letter of intent and the expected benefits thereof, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
First Full Month of Post-Acquisition Profitability Highlights Platform Scale, Improving Margins and a Clear Path Toward Cash-Flow Positivity in 2026
TORONTO, ON / ACCESS Newswire / March 18, 2026 / Nextech3D.ai (the “Company”) (CSE:NTAR)(OTCQB:NEXCF)(FSE:1SS), a leading provider of an AI‑powered operating system for the global events and experiences economy, today announced that Krafty Labs, a division acquired in January 2026, achieved profitability in February 2026, its first full month of operations following the acquisition. The Company also reported continued progress in operating efficiency and margin expansion, reinforcing management’s belief that Nextech3D.ai is advancing toward cash‑flow positive operations in 2026, subject to execution and market conditions.
In February 2026, Krafty Labs generated approximately $130,000 in revenue, delivering a 66% gross margin, or approximately $85,000, and a net margin of approximately 55%, or $71,000. Management believes this performance validates the strength of the underlying business, the quality of the acquisition, and the operating leverage available within Nextech3D.ai’s platform‑driven model.
“The strength and depth of our customer base – hundreds of Tier 1 blue‑chip accounts alongside a rapidly expanding enterprise pipeline – gives us increasing confidence in the scalability of our platform,” said Evan Gappelberg, Chief Executive Officer of Nextech3D.ai.
“Krafty Labs achieving profitability in its first full month post‑acquisition demonstrates how scale, margin expansion, and operational discipline are coming together. With this momentum, we believe Nextech3D.ai is building a clear and achievable path toward cash‑flow positivity in 2026.”
Platform at Scale
Nextech3D.ai operates a platform‑centric AI technology model designed to support multiple solutions across event technology, spatial computing, and enterprise deployments. Unlike single‑product SaaS models, the Company’s platform is architected to capture value across multiple customer entry points, use cases, and expansion paths.
Management believes this structure enables Nextech3D.ai to efficiently onboard customers, expand relationships over time, and support increasingly complex enterprise and government deployments – including AI‑driven matchmaking and engagement solutions – while diversifying revenue streams and reducing reliance on any single customer or product.
Estimated Annual Recurring Revenue and Margin Profile
Based on existing customer contracts and prior‑year activity, Nextech3D.ai estimates total Annual Recurring Revenue (ARR) of approximately $3.0 million associated with its current customer base. While not all of this revenue is expected to be recognized in 2026, management believes this ARR profile reflects the strength, scalability, and durability of the Company’s recurring revenue model.
Importantly, this ARR is generated from a favorable mix of high‑margin platform components operating at approximately 95% gross margin and services operating at approximately 66% gross margin, which management believes positions the Company to achieve a blended gross margin of approximately 80% in 2026. As this high‑quality recurring revenue base continues to scale, management believes the resulting operating leverage supports profitability momentum and reinforces the Company’s path toward cash‑flow positivity.
Customer Composition and Land‑and‑Expand Strategy
The Company’s ARR is anchored by hundreds of Tier 1 blue‑chip customers, providing a stable and diversified revenue foundation, while a fast‑growing pipeline of Tier 2 and Tier 3 enterprise customers continues to increase average deal sizes and platform engagement. This dynamic reflects Nextech3D.ai’s land‑and‑expand strategy, supporting sustained adoption, improving revenue quality, and long‑term platform monetization.
Estimated ARR by Customer Tier
Tier
Revenue Range
2026 Estimated ARR
Tier 1
$0 – $20K
$2.1M
Tier 2
$20K – $50K
$0.52M
Tier 3
$50K – $200K
$0.45M
Total Estimated ARR
~$3.0M
Expanding Enterprise Engagement
Nextech3D.ai continues to see growing adoption of its AI‑powered enterprise engagement platform across associations, enterprises, and large‑scale event organizers. Customers utilize solutions for registration, ticketing, floor plans, AI‑driven matchmaking, audience engagement, analytics, and related services.
Management believes the early profitability of Krafty Labs further demonstrates the Company’s ability to integrate accretive acquisitions, enhance platform capabilities, and improve operating efficiency as the business scales.
About Nextech3D.ai
Nextech3D.ai (OTCQB:NEXCF)(CSE:NTAR)(FSE:1SS) is building an AI‑powered enterprise engagement operating system for the global events and experiences economy. The Company provides AI infrastructure for real‑world experiences, enabling organizations to manage events, physical spaces, and audience engagement through intelligent software platforms.
Nextech3D.ai serves over 500+ customers, including small businesses and Fortune 1000 enterprises, through its ecosystem of platforms including Eventdex, Map D, and Krafty Labs, as part of its strategy to consolidate the fragmented event technology industry into a unified AI platform.
The Company also utilizes blockchain technology as a fraud‑resistant verification and certification layer, supporting applications such as blockchain‑based ticketing, credential verification, and digital event accreditation.
This press release contains forward‑looking statements within the meaning of applicable Canadian securities legislation. Forward‑looking statements include, but are not limited to, statements regarding management’s objectives, anticipated operational performance, margin expectations, integration efforts, and future business prospects. Forward‑looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update forward‑looking statements, except as required by applicable securities laws.
Redefining Human Capital Management Across Aviation, Nuclear Power, AI, Robotics and Agentic AI
MIAMI, FL / ACCESS Newswire / March 18, 2026 / TGI Solar Power Group Inc. (OTC PINK:TSGT) (“TGI” or the “Company”), a diversified industrial, technology and environmentally sustainable real estate development company is pleased to announce it has entered into a landmark strategic partnership with MetaSense Inc., a global leader in staffing augmentation and human capital management.
This alliance is designed to provide world-class, specialized workforce solutions across TGI’s most technically demanding sectors, including nuclear power, aviation, robotics, and agentic AI. As TGI continues to expand its global footprint in sustainable infrastructure and advanced technology, the partnership with MetaSense ensures a steady pipeline of elite, safety-cleared professionals to execute high-stakes projects.
Strategic Objectives of the Alliance
The partnership will focus on addressing talent shortages in critical industries where operational precision and safety are paramount:
Nuclear Power & SMR Development: Providing health physicists, reactor operators, and plant life-extension experts for TGI’s energy initiatives.
Aviation & Aerospace: Supplying licensed aircraft maintenance engineers and avionics specialists to support international charter and cargo operations.
AI & Robotics: Deploying specialized engineers to integrate agentic AI and automated systems into TGI’s industrial logistics and smart city frameworks.
Management Commentary
“The industries we serve are defining the future of energy, transportation, and intelligent systems. Securing the right human capital is as critical as the technology itself. This partnership with MetaSense allows TGI to scale rapidly while maintaining the highest standards of compliance and technical excellence.” – Samuel Epstein, Chief Executive Officer, TGI Solar Power Group Inc.
“Together, MetaSense and TGI will deliver workforce solutions tailored to the global economy’s most specialized sectors. By leveraging our recruitment methodologies alongside TGI’s deep project portfolios, we are building a bridge between elite talent and visionary projects.” – Jatin V. Mehta, CEO, MetaSense Inc.
About TGI Solar Power Group Inc.
TGI Solar Power Group Inc. is a diversified holding company focused on sustainable infrastructure, circular economy solutions, and advanced technology integration. Through its subsidiaries and strategic partnerships, TGI develops large-scale industrial projects, including smart city infrastructure, waste-to-energy systems, and next-generation automotive manufacturing.
About MetaSense Inc.
MetaSense Inc. is a premier healthcare and technology staffing firm specializing in human capital management. With a focus on high-stakes industries, MetaSense provides comprehensive staffing augmentation, compliance frameworks, and global talent pipelines for aviation, nuclear energy, and AI-driven sectors.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected.
